Nivedita Nagam, MD
Rheumatology · Chesterfield, MONPI 1437461290
Payments from drug & device makers
Across 512 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- AbbVie$2K
- Johnson & Johnson$1K
- AstraZeneca$774
- Pfizer$723
- UCB, Inc.$485
- plus $3K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 97 | $2,087 |
| AbbVie(2 entities) | 75 | $1,504 |
| Johnson & Johnson | 65 | $1,165 |
| AstraZeneca(2 entities) | 37 | $774 |
| Pfizer | 57 | $723 |
| UCB, Inc. | 24 | $485 |
| E.r. Squibb & Sons, L.L.C. | 30 | $428 |
| Novartis | 21 | $388 |
| GSK | 28 | $371 |
| Lilly USA, LLC | 21 | $325 |
| Sandoz | 9 | $160 |
| Genentech USA, Inc. | 7 | $130 |
| Boehringer Ingelheim | 6 | $109 |
| Sanofi | 6 | $106 |
| Amarin Pharma, Inc. | 4 | $88 |
| Janssen Scientific Affairs, LLC | 2 | $46 |
| Ironwood Pharmaceuticals, Inc | 3 | $40 |
| Bristol Myers Squibb | 2 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Novo Nordisk | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Sanofi-aventis U.S. LLC | 1 | $24 |
| SK Life Science, Inc. | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $20 |
| Aurinia Pharma U.S., Inc. | 1 | $20 |
| Organon | 1 | $18 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Fresenius Kabi USA, LLC | 1 | $17 |
| Eisai Inc. | 1 | $16 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| Grifols USA, LLC | 1 | $15 |
| Sunovion Pharmaceuticals Inc. | 1 | $15 |
| Medexus Pharma, Inc. | 1 | $13 |
How this compares
$9,273 in reported general payments places this provider in the 70th percentile of 134 rheumatology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other rheumatology in Chesterfield
- James EstherChesterfield$10K
- Donica BakerChesterfield$9K
- Faye CohenChesterfield$7K
- Linda HuntChesterfield$7K
- Keith BernsteinChesterfield$5K
- John ErvinKansas City$18.7M
- David TrueSpringfield$15.8M
- Ghaith NoaisehKansas City$1.6M
- Anne WinklerCarthage$1.6M
- Alfred KimSaint Louis$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.